Literature DB >> 11937497

Effects of nitroglycerin on soluble guanylate cyclase: implications for nitrate tolerance.

Jennifer D Artz1, Bryan Schmidt, John L McCracken, Michael A Marletta.   

Abstract

Soluble guanylate cyclase (sGC) is a heterodimeric hemoprotein that catalyzes the conversion of GTP to cGMP. Upon binding NO to its heme cofactor, purified sGC was activated 300-fold. sGC was only activated 67-fold by nitroglycerin (GTN) and Cys; and in the absence of Cys, GTN did not activate sGC. Electronic absorption spectroscopy studies showed that upon NO binding, the Soret of ferrous sGC shifted from 431 to 399 nm. The data also revealed that activation of sGC by GTN/Cys was not via the expected ferrous heme-NO species as indicated by the absence of the 399 nm heme Soret. Furthermore, EPR studies of the reaction of GTN/Cys with sGC confirmed that no ferrous heme-NO species was formed but that there was heme oxidation. Potassium ferricyanide is known to oxidize ferrous sGC to the ferric oxidation state. Spectroscopic and activity data for the reactions of sGC with GTN alone or with K(3)Fe(CN)(6) were indistinguishable. These data suggest the following: 1) GTN/Cys do not activate sGC via GTN biotransformation to NO in vitro, and 2) in the absence of added thiol, GTN oxidizes sGC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937497     DOI: 10.1074/jbc.C200170200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

Review 2.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 3.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles.

Authors:  B Mayer; M Beretta
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

4.  Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance.

Authors:  Karsten Sydow; Andreas Daiber; Matthias Oelze; Zhiqiang Chen; Michael August; Maria Wendt; Volker Ullrich; Alexander Mülsch; Eberhard Schulz; John F Keaney; Jonathan S Stamler; Thomas Münzel
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

5.  Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.

Authors:  L S Hoffmann; P M Schmidt; Y Keim; S Schaefer; H H H W Schmidt; J P Stasch
Journal:  Br J Pharmacol       Date:  2009-05-18       Impact factor: 8.739

6.  Effects of nitroglycerin/L-cysteine on soluble guanylate cyclase: evidence for an activation/inactivation equilibrium controlled by nitric oxide binding and haem oxidation.

Authors:  Antonius C F Gorren; Michael Russwurm; Alexander Kollau; Doris Koesling; Kurt Schmidt; Bernd Mayer
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

7.  Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.

Authors:  Bobby Nossaman; Edward Pankey; Philip Kadowitz
Journal:  Crit Care Res Pract       Date:  2012-02-28

Review 8.  Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction.

Authors:  Yuliya Mikhed; Andreas Daiber; Sebastian Steven
Journal:  Int J Mol Sci       Date:  2015-07-13       Impact factor: 5.923

9.  Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: evidence for the activation of purified soluble guanylate cyclase through direct formation of nitric oxide.

Authors:  Alexander Kollau; Alexandra Hofer; Michael Russwurm; Doris Koesling; Wing Ming Keung; Kurt Schmidt; Friedrich Brunner; Bernd Mayer
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.